Your solution

Bendamustine HCI

CAS Monohydrate: 1374784-02-7 CAS Anhydrous: 3543-75-7

Back to results
Bendamustine HCI
Bendamustine hydrochloride is an alkylating antitumor agent indicated for the treatment of patients with:
  • Chronic lymphocytic leukaemia
  • Indolent B-cell non-Hodgkin’s lymphoma refractory to rituximab
  • Multiple myeloma, in combination with Prednisone
Bendamustine is on the World Health Organization model list of essential medicines.

Therapeutic group
Antineoplastic agents, alkylating agents
ATC code: L01AA09
Your selection
Request factsheet Request technical support
Bendamustine HCI

Key dosage forms

  • Powder for concentrate for solution for infusion (25 mg, 100 mg)
  • Concentrate for solution for infusion (45 mg/mL)

Features

  • Monohydrate successfully registered in EU & under submission in US
  • Audited by several customers & US FDA
  • Monohydrate and anhydrous available
  • Stable quality API
  • Reliable supply

Some brand names

  • RIBOMUSTIN®
  • TREANDA® (TEVA)
  • LEVACT®

How can we support you with Bendamustine HCI?

I am looking for..
Creating a world of opportunity

This website uses cookies to improve your user experience

We use cookies for a variety of purposes, such as website functionality and helping target our marketing activities. Click "accept" to accept our cookies. You can change the cookie settings by clicking "change settings".